Lupin launches Eslicarbazepine Acetate Tablets in the United States

Global pharma major Lupin Limited (Lupin) today announced that it has launched Eslicarbazepine Acetate Tablets, 200 mg, 400 mg, 600 mg, and 800 mg, following the approval of its Abbreviated New Drug Application (ANDA) from the U.S. FDA. Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity.

Eslicarbazepine Acetate Tablets, 200 mg, 400 mg, 600 mg, and 800 mg are bioequivalent to Aptiom® Tablets, 200 mg, 400 mg, 600 mg, and 800 mg, of Sumitomo Pharma America, Inc., and indicated for the treatment of partial-onset seizures in patients 4 years of age and older.

Eslicarbazepine Acetate Tablets (RLD Aptiom®) had estimated annual sales of USD 395 million in the U.S. (IQVIA MAT March 2025).

Shares of Lupin Limited was last trading in BSE at Rs. 2070.95 as compared to the previous close of Rs. 2048.90. The total number of shares traded during the day was 50549 in over 2387 trades.

The stock hit an intraday high of Rs. 2074.40 and intraday low of 2025.80. The net turnover during the day was Rs. 104380264.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals EslicarbazepineAcetateTablets US